US on a steady growth path; sizeable launches lined up in FY23: Cipla continues to see strong traction for its gProventil (albuterol inhaler) launch in the US where it has garnered 13.2% volume share. 4Q US sales at $138 m declined 2% qoq on lack of meaningful launches.
from The Financial Express https://ift.tt/3waTs56
https://ift.tt/eA8V8J HSBC
from The Financial Express https://ift.tt/3waTs56
https://ift.tt/eA8V8J HSBC
Comments
Post a Comment